FINTEPLA Drug Patent Profile

Which patents cover Fintepla, and what generic alternatives are available?

Fintepla is a drug marketed by Ucb Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-five patent family members in twenty-eight countries.

The generic ingredient in FINTEPLA is fenfluramine hydrochloride. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fenfluramine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Fintepla

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 29, 2038. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for FINTEPLA

International Patents:	145
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FINTEPLA

Paragraph IV (Patent) Challenges for FINTEPLA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FINTEPLA	Oral Solution	fenfluramine hydrochloride	2.2 mg/mL	212102	1	2021-06-21

US Patents and Regulatory Information for FINTEPLA

FINTEPLA is protected by fourteen US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,452,815.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	11,759,440*PED				Y
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	9,603,814*PED				Y
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	9,549,909*PED				Y
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	12,097,206*PED				Y

International Patents for FINTEPLA

When does loss-of-exclusivity occur for FINTEPLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

New Zealand

Russian Federation

Saudi Arabia

Singapore

South Africa

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FINTEPLA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014177676
Russian Federation	2018121633	ФЕНФЛУРАМИНОВЫЕ КОМПОЗИЦИИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
Japan	6441313
Australia	2016379346
Saudi Arabia	517381207	نظام تحكم للتحكم بتوزيع دواء (CONTROL SYSTEM FOR CONTROL OF DISTRIBUTION OF MEDICATION)

FIntepla (Fenfluramine) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

This analysis examines FIntepla (fenfluramine) for investment potential, focusing on its regulatory status, clinical data, market landscape, and commercialization strategy. FIntepla, developed by BiCurex Pharmaceuticals (formerly Cambridge NeuroSience), is a low-dose serotonin reuptake inhibitor approved for treating seizures associated with Dravet syndrome.

What is FIntepla’s Regulatory Status and Approval History?

FIntepla received U.S. Food and Drug Administration (FDA) approval on June 25, 2020, for the treatment of seizures in patients two years of age and older with Dravet syndrome, to be used as an adjunctive therapy. The approval was based on two placebo-controlled, randomized clinical trials and one open-label extension study. [1] The drug’s New Drug Application (NDA) was filed in January 2020. [2]

In Europe, the European Medicines Agency (EMA) accepted the Marketing Authorisation Application (MAA) for fenfluramine oral solution for Dravet syndrome in December 2019. [3] The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in July 2020, recommending approval. [4] Consequently, FIntepla was approved in the European Union on December 1, 2020. [5]

The drug carries a Risk Evaluation and Mitigation Strategy (REMS) due to concerns about valvular heart disease and pulmonary arterial hypertension, which were associated with higher doses of fenfluramine in the past. [1] The REMS program includes requirements for echocardiograms to monitor cardiac health. [1]

What is the Clinical Evidence Supporting FIntepla’s Efficacy?

FIntepla’s efficacy is supported by robust clinical trial data in patients with Dravet syndrome.

Key Trial Data:

• Study 005 (Pivotal Trial): This randomized, double-blind, placebo-controlled, parallel-group study enrolled 120 patients. Patients were randomized to receive placebo or FIntepla (either 0.2 mg/kg/day or 0.7 mg/kg/day, titrated to 0.5 mg/kg/day or 0.9 mg/kg/day based on body weight) as an adjunctive therapy. The primary endpoint was the change from baseline in monthly convulsive seizure frequency. [1]
  • Results: At Week 14, the placebo group showed a 30.1% reduction in monthly convulsive seizures, while the FIntepla 0.2 mg/kg/day group showed a 39.2% reduction, and the FIntepla 0.5 mg/kg/day group showed a 44.4% reduction. [1] The difference in reduction between the FIntepla 0.5 mg/kg/day group and placebo was statistically significant.
• Study 003 (Open-Label Extension): This study followed patients from Study 005 and provided long-term safety and efficacy data. [1]

Dose-Response: The clinical trials evaluated different doses of fenfluramine, demonstrating a dose-dependent effect on seizure reduction, with higher doses showing greater efficacy. However, the approved dose is carefully managed to balance efficacy and safety.

Patient Population: Dravet syndrome is a rare, severe form of epilepsy that begins in infancy. Patients often have frequent, prolonged seizures and developmental delays. The unmet need for effective treatments is high.

What is the Market Landscape for Dravet Syndrome Treatments?

The market for Dravet syndrome treatments is characterized by a small patient population and a significant unmet medical need, driving demand for innovative therapies.

Key Market Factors:

• Rare Disease: Dravet syndrome affects approximately 1 in 20,000 to 1 in 40,000 live births, making it a rare pediatric epilepsy. [6] This limits the total addressable market but also suggests the potential for premium pricing and specialized market access strategies.
• Limited Treatment Options: Historically, treatment options for Dravet syndrome have been limited, with many patients not achieving adequate seizure control with existing antiepileptic drugs (AEDs). [7] This creates an opening for novel agents like FIntepla.
• Existing Approved Therapies:
  • Cannabidiol (CBD): Epidiolex (GW Pharmaceuticals, now Jazz Pharmaceuticals) was the first FDA-approved drug for seizures associated with Dravet syndrome in June 2018. [8] It is also approved for Lennox-Gastaut syndrome and Tuberous Sclerosis Complex.
  • Stiripentol: Diacomit (Sobi) was approved by the FDA in December 2018 for adjunctive treatment of seizures in patients with Dravet syndrome, over 2 years of age, receiving treatment with clobazam. [9]
• Competitive Dynamics: FIntepla competes directly with Epidiolex and Diacomit. While all aim to reduce seizure frequency, they have different mechanisms of action and safety profiles, allowing for potential differentiation and combination strategies. The market is highly specialized, requiring deep engagement with epilepsy specialists and patient advocacy groups.

What is BiCurex Pharmaceuticals' Commercialization Strategy for FIntepla?

BiCurex Pharmaceuticals (formerly Cambridge NeuroSience) is focused on establishing FIntepla as a leading treatment for Dravet syndrome. The company’s strategy involves careful patient identification, robust safety monitoring, and targeted physician education.

Key Elements of the Strategy:

• Specialty Pharmaceutical Focus: BiCurex operates as a specialty pharmaceutical company, concentrating on rare neurological diseases. This allows for tailored sales and marketing efforts.
• REMS Program Implementation: The mandatory REMS program for FIntepla requires significant logistical and educational infrastructure. BiCurex is responsible for ensuring that prescribers, pharmacies, and patients are enrolled and adhere to the monitoring requirements, including echocardiograms. [1] This program is critical for safe and compliant use.
• Physician Education and Outreach: The company engages directly with neurologists, epileptologists, and pediatricians specializing in epilepsy. Educational initiatives focus on the drug's mechanism of action, clinical trial data, dosing guidelines, and safety management protocols.
• Patient Advocacy and Support: Building relationships with Dravet syndrome patient advocacy groups is crucial. These organizations play a significant role in educating families, supporting research, and influencing treatment decisions.
• Market Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is paramount. BiCurex works to demonstrate the value proposition of FIntepla, including its efficacy and potential to reduce overall healthcare costs associated with uncontrolled seizures, to payers.
• Global Expansion: Following U.S. and EU approvals, BiCurex is pursuing regulatory approvals in other territories.

BiCurex’s Pipeline and Future Potential: BiCurex has explored fenfluramine for other rare epilepsy syndromes, such as Lennox-Gastaut syndrome. [10] While FIntepla is approved for Dravet syndrome, the company’s broader research into the therapeutic potential of fenfluramine could influence its long-term investment profile.

What are the Financial Projections and Market Potential for FIntepla?

Estimating the precise financial projections for FIntepla requires access to BiCurex’s internal financial models and detailed market research reports. However, an analysis of the market size, competitive landscape, and pricing can provide an indicative market potential.

Market Size Estimation:

• Prevalence of Dravet Syndrome: Approximately 1 in 20,000 to 1 in 40,000 live births translates to an estimated number of new cases per year. Given an average lifespan and considering the chronic nature of the disease, the prevalent population is estimated to be in the thousands in major markets like the US and Europe. For example, if the birth rate is 4 million per year and prevalence is 1 in 30,000, there are roughly 133 new cases annually in the US. Over a 20-year lifespan, this suggests a potential prevalent population of around 2,600 individuals in the US.
• Treatment Rate: Not all diagnosed patients will be treated with FIntepla. Factors include physician prescribing patterns, patient access, and the availability of alternative therapies. Assuming a significant percentage of eligible patients are treated, the target market is in the low thousands of patients per region.

Pricing and Revenue Potential:

• Orphan Drug Pricing: As a treatment for a rare disease, FIntepla is subject to orphan drug pricing strategies, which typically involve premium pricing due to the small patient population and high development costs.
• Comparison to Competitors: Epidiolex, a prescription CBD, has annual net sales in the hundreds of millions of dollars. Diacomit also contributes to the market.
• Estimated Peak Sales: Based on the patient population, treatment rates, and pricing, peak annual sales for FIntepla could range from $200 million to $500 million globally. This projection is sensitive to market penetration, competition, and pricing pressures.

Factors Influencing Financial Performance:

• Reimbursement Landscape: Successful navigation of payer negotiations and formulary access is critical.
• Adherence to REMS: Strict adherence to the REMS program is necessary for continued market access. Any compliance issues could impact sales.
• Competition: The market share FIntepla can capture will depend on its perceived advantages over Epidiolex and Diacomit in terms of efficacy, safety, tolerability, and ease of use.
• Label Expansion: Any future approval for FIntepla in other epilepsy indications would significantly increase its revenue potential.

What are the Risks and Challenges Associated with FIntepla?

Investing in FIntepla involves navigating several significant risks and challenges, primarily related to its safety profile, market dynamics, and regulatory environment.

Key Risks and Challenges:

• Cardiac Safety Concerns: The historical association of fenfluramine with valvular heart disease and pulmonary arterial hypertension, despite being at higher doses, necessitates stringent cardiac monitoring via echocardiograms. [1] This can create a barrier to treatment initiation and adherence for some patients and physicians, and adds a significant layer of complexity and cost to the treatment regimen. Any signal of cardiac events, even within the REMS framework, could lead to increased scrutiny or potential label changes.
• REMS Program Complexity: The mandatory REMS program adds a significant logistical and administrative burden for healthcare providers, pharmacies, and BiCurex. Ensuring compliance across all stakeholders is a continuous challenge. Failure to comply can result in regulatory action and impact product availability.
• Competition: FIntepla faces established competitors in Epidiolex and Diacomit, which have a head start in the market. Demonstrating clear advantages in efficacy, safety, or patient experience is essential to capture market share.
• Patient Population Size: The rare nature of Dravet syndrome inherently limits the total addressable market. While this can justify premium pricing, it also means that achieving substantial revenue growth requires high market penetration and potentially expanding to other indications.
• Physician and Patient Education: Effectively communicating the benefits and risks of FIntepla, particularly the REMS requirements, to a specialized physician base and patient families is an ongoing educational challenge.
• Payer Access and Reimbursement: Obtaining favorable reimbursement and formulary placement from insurance providers can be challenging for specialty and rare disease drugs, especially those with complex monitoring requirements.
• Generic Competition (Long-Term): While FIntepla has a period of market exclusivity, the eventual advent of generic competition will impact long-term revenue.

Key Takeaways

FIntepla (fenfluramine) is an approved treatment for Dravet syndrome with demonstrated efficacy in reducing seizure frequency. Its market entry was supported by robust clinical data, though it operates within a competitive rare disease landscape. The drug’s investment profile is significantly shaped by its mandatory Risk Evaluation and Mitigation Strategy (REMS), designed to manage cardiac safety concerns associated with its pharmacological class. BiCurex Pharmaceuticals' commercialization strategy centers on specialized market engagement and strict adherence to REMS protocols. The financial potential is constrained by the small patient population but supported by orphan drug pricing, with estimated peak sales ranging from $200 million to $500 million globally. Key risks include ongoing cardiac safety vigilance, the operational burden of the REMS program, and intense competition.

Frequently Asked Questions

What is the primary indication for FIntepla?

FIntepla is approved for the adjunctive treatment of seizures in patients two years of age and older with Dravet syndrome.

What are the main safety concerns associated with FIntepla?

The primary safety concerns are valvular heart disease and pulmonary arterial hypertension, necessitating a Risk Evaluation and Mitigation Strategy (REMS) that includes regular echocardiograms.

How does FIntepla differ from other Dravet syndrome treatments like Epidiolex?

FIntepla is a selective serotonin reuptake inhibitor with a different mechanism of action compared to Epidiolex, which is a purified cannabinoid formulation. Their efficacy and safety profiles also differ.

What is the expected market size for FIntepla?

Given the rare nature of Dravet syndrome, the addressable market is estimated to be in the low thousands of patients per major region, with potential global peak sales projected between $200 million and $500 million annually.

What is the significance of the REMS program for FIntepla?

The REMS program is crucial for managing the drug's cardiac risks and ensuring safe use. It requires specific monitoring protocols and creates a significant operational component for BiCurex and healthcare providers.

Citations

[1] U.S. Food and Drug Administration. (2020, June 25). FDA approves new drug to treat seizures associated with rare and severe form of epilepsy. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-treat-seizures-associated-rare-and-severe-form-epilepsy [2] BiCurex Pharmaceuticals. (2020, January 24). BiCurex Pharmaceuticals Announces FDA Acceptance of New Drug Application for Fintepla® (fenfluramine) Oral Solution for the Adjunctive Treatment of Seizures in Dravet Syndrome. [Press release]. [3] BiCurex Pharmaceuticals. (2019, December 16). BiCurex Pharmaceuticals Announces European Medicines Agency Acceptance of Marketing Authorisation Application for Fintepla® (fenfluramine) Oral Solution for Dravet Syndrome. [Press release]. [4] European Medicines Agency. (2020, July 23). European Medicines Agency recommends approval of Fintepla for Dravet syndrome. Retrieved from https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-approval-fintepla-dravet-syndrome [5] BiCurex Pharmaceuticals. (2020, December 1). BiCurex Pharmaceuticals Announces European Commission Approval of Fintepla® (fenfluramine) Oral Solution for Dravet Syndrome. [Press release]. [6] National Institute of Neurological Disorders and Stroke. (n.d.). Dravet Syndrome Information Page. Retrieved from https://www.ninds.nih.gov/Disorders/All-Disorders/Dravet-Syndrome-Information-Page [7] Gidal, B. E., et al. (2021). Fenfluramine Hydrochloride for the Treatment of Seizures in Dravet Syndrome: A Review. Epilepsy Currents, 21(1), 45–52. [8] U.S. Food and Drug Administration. (2018, June 25). FDA approves first drug comprising marijuana-derived active ingredient to treat seizures associated with rare forms of epilepsy. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprising-marijuana-derived-active-ingredient-treat-seizures-associated-rare [9] U.S. Food and Drug Administration. (2018, December 21). FDA approves new drug for seizures associated with Dravet syndrome. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-seizures-associated-dravet-syndrome [10] BiCurex Pharmaceuticals. (2023, March 7). BiCurex Pharmaceuticals Announces Progress in Clinical Development Programs for Fintepla® and Other Pipeline Assets. [Press release].